Glycovax Pharma Inc. has entered into a strategic collaboration with the National Research Council of Canada (NRC) and the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa infections, with expected utility for patients with cystic fibrosis and hospitalized individuals at risk of nosocomial infections.
Oligomeric forms of α-synuclein are increasingly recognized as the primary neurotoxic species in Parkinson’s disease (PD) and other synucleinopathies, contributing to synaptic dysfunction, mitochondrial impairment and the prion-like propagation of pathology. Targeting these early aggregates represents a promising strategy for disease modification.
The transition from complex and costly ex vivo strategies to platforms that enable direct cellular intervention within the body, known as in vivo therapies, is marking a paradigm change in the field of gene and cell therapies by simplifying manufacturing, improving tissue targeting and expanding clinical access to treatments.
Merck Sharp & Dohme LLC (MSD) has synthesized new N-oxide derivative targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of HIV infection.
Northern Illinois University and Stream Neuroscience Inc. have patented benzothiazole derivatives acting as phosphodiesterase‑4 (PDE4) inhibitors and reported to be useful for the treatment of cancer, cognitive, inflammatory and mood disorders.
Simcere Zaiming Pharmaceutical Co. Ltd. has described membrane‑associated tyrosine‑ and threonine‑specific Cdc2‑inhibitory kinase (PKMYT1) inhibitors for cancer.
Bryet US Inc. has received Australian Human Research Ethics Committee (HREC) approval for its first-in-human study of ML-016 for patients with advanced cancer with lung and/or liver involvement. Enrollment in the phase I/II trial will begin early next year.
The pathogenesis of multiple sclerosis (MS) has been tied to ineffective immune control of Epstein-Barr virus-driven autoimmune responses. Patients with MS are deficient in protective adaptive natural killer cells (pNK cells) in contrast to healthy individuals. These pNK cells are positive for NKG2A, NKG2C and NKG2D and recognize and kill autoreactive B cells in a selective and efficient manner.
RSS
